Epsilogen

About:

Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.

Top Investors: Innovate UK, AlbionVC, Novartis Venture Fund, Schroders Capital, British Patient Capital

Description:

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

Total Funding Amount:

52.5M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2016-01-01

Contact Email:

info(AT)igemtherapeutics.com

Founders:

Sophia Karagiannis

Number of Employees:

11-50

Last Funding Date:

2024-09-09

IPO Status:

Private

Industries: